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Abstract 
At present, the best hope for eliminating HIV 
transmission and bringing the epidemic of HIV to 
an end lies in the use of anti-retroviral therapy for 
prevention, a strategy referred to variously as Test 
and Treat (T&T), Treatment as Prevention (TasP) 
or Treatment centred Prevention (TcP). One of the 
key objections to the use of T&T to stop 
transmission concerns the role of the acute phase in 
HIV transmission. The acute phase of infection 
lasts for one to three months after HIV-
seroconversion during which time the risk of 
transmission may be ten to twenty times higher, per 
sexual encounter, than it is during the chronic phase 
which lasts for the next ten years. Regular testing 
for HIV is more likely to miss people who are in 
the acute phase than in the chronic phase and it is 
essential to determine the extent to which this 
might compromise the impact of T&T on HIV-
transmission.  
 Here we show that 1) provided the initial 
epidemic doubling time is about 1.0 to 1.5 years, as 
observed in South Africa, random testing with an 
average test interval of one year will still bring the 
epidemic close to elimination even if the acute 
phase lasts for 3 months during which time 
transmission is 26 times higher than in the chronic 
phase; 2) testing people regularly at yearly intervals 
is significantly more effective then testing them 
randomly; 3) testing people regularly at six monthly 
intervals and starting them on ART immediately, 
will almost certainly guarantee elimination.  
 In general it seems unlikely that elevated 
transmission during the acute phase is likely to 
change predictions of the impact of treatment on 
transmission significantly. Other factors, in 
particular age structure, the structure of sexual 
networks and variation in set-point viral load are 
likely to be more important and should be given 
priority in further analyses. 
Introduction 
We can estimate the relative risk of infection during 
the acute and chronic stages of infection in two 
ways. We can estimate it indirectly if we have data 
on the viral load in the acute and chronic stages and 
data on the probability of a transmission event as a 
function of viral load.1-6 We can estimate it directly 
if we have a sero-incident cohort with a short 
follow up time and if we can measure the number 
of infection events in each stage.8 Both methods 
require a sero-incident cohort and repeated 
measurements of the viral load. Cohort data are 
always difficult to obtain and cohorts of discordant 
couples will become increasingly biased with time 
as those that are most likely to infect their partners 
do so and are removed from the cohort. 
Nevertheless, these are the data that we have. 
Indirect estimates 
We first ask: how does viral load vary from initial 
infection through sero-conversion and the acute 
phase to the chronic phase and eventually to the 
final phase shortly before death? The most useful 
data in this regard, based on two sets of archived 
samples from HIV infected plasma donors, are 
from Fiebig et al.7 Figure 1 shows the observed 
median values of viral load as a function of time 
since infection.7 The fitted (green) line is  
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Figure 1. Median values of viral load as a function of 
time since infection.7 Error bars are 95% confidence 
limits on median values. Green lines: maximum 
likelihood fit (see text); red lines 95% confidence bands. 
Data for individuals (not shown) vary by about ±1.5 logs. 
 In Equation 2, N scales overall transmission up 
or down, the first logistic function l in the curly 
brackets increases with time at a rate α1 reaching 
half the maximum value at time δ1, the second 
decreases with time at a rate α2 reaching half the 
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maximum value at time δ2. β is the asymptotic 
value to which the viral load converges during the 
chronic phase. In short, the viral load increases at a 
rate α1 to a peak value from which it converges 
downwards at a rate α2 to an asymptote at β. The 
median value of the log10(viral load) during the 
chronic phase is 4.09 ± 0.31 and at the peak of the 
acute phase is 5.45 ± 0.15. The acute phase lasts 
from day 8 to day 70 after sero-conversion so that 
the duration of the acute phase, DAP = 62 days, 
during which time the average value of the median 
viral load is 4.73 ± 0.02 for an average increase of 
0.7 logs or a factor of 100.7 = 5.0 (3.2−7.9) over the 
value during the chronic stage of infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. HIV transmission probability per year as a 
function of viral load. A: Attia et al.;1 B: Donnell et al.;3 
C: Lingappa et al.6 Significance levels for the fitted lines 
are A: 0.778; B: 0.376; C: 0.110. If we assume a power 
law relationship between transmission and viral load the 
significance levels for the best fit curves are A: 0.0006; 
B: 0.302; C: 0.309. 
 There are three sets of data on the risk of 
infection per unit time as a function of viral load1,3,6 
(Figure 2). The simplest model of the relationship 
between viral load and transmission assumes that 
the former increases linearly with the latter (but see 
also Appendix 1). However, the data suggest that 
transmission saturates at high viral load and we 
therefore assume a relationship of the following 
form: 
 ( )1 e VT ρα −= −  3 
where T is the probability of transmission per year. 
At low viral loads transmission increases linearly as 
T = αρV so that the probability of infection per 
virion per mm3 is αρ, transmission saturates at α 
transmissions per year and we can define V*, the 
viral load time at which transmission saturates, as 
the intercept of the initial linear increase with the 
asymptotic value so that 
 1*V ρ= . 4 
 The fits in Figure 2 give the values in Table 1. 
Allowing for the small amount of over-dispersion 
in the estimates we see that for low viral loads the 
probability of infection is 2.42×10−6 
(1.14×10−6−5.13×10−6) times the viral load per 
mm3 and at high viral loads transmission saturates 
when the viral load is 4.37±0.29 logs.  
 We can now estimate the probability of 
transmission at the peak of the acute phase, when 
the log10 (median viral load) is 5.45, and in the 
chronic phase, when the log10 (median viral load), 
using each of the three data sets. The ratio of the 
pairs of estimates gives RR, the relative risk of 
infection, per unit time, in the acute and the chronic 
phase as RR = 2.1 (1.1−3.9). 
Table 1. The viral load at which transmission saturates; 
the probability of infection per virion per mm3; and the 
relative risk (RR) of infection in the acute and chronic 
phases. 
Reference 
Log10(sat. 
viral 
load/mm3) 
(Prob. infection/ 
virion/mm3/yr) 
×106 
RR acute v. 
chronic phase
Attia1 4.05 ± 0.44 7.46 (4.00−14.9) 1.4 (0.6−3.5)
Donnell3 4.40 ± 0.39 1.30 (0.72−2.86) 2.5 (0.7−8.6)
Lingappa6 4.56 ± 0.36 1.46 (0.89−3.11) 3.4 (1.0−11.3)
Average 4.37 ± 0.29 2.42 (1.14−5.13) 2.1 (1.1−3.9)
 
Direct estimates 
The most widely cited direct estimates of the 
relative transmission in the acute and chronic stages 
of HIV-infection are based on the Uganda study of 
Wawer et al.8 The most reliable data, in this regard, 
are those from the incidence cohort in which there 
were 10 transmission events among 23 couples who 
had 1221 coital acts in the first six months after 
seroconversion and 2 transmission events among 
the remaining 13 couples who had 1313 coital acts 
in months 6 to 15 after seroconversion. This gives a 
relative risk of transmission RR = 3.4 (0.7−17.6). 
Wawer et al.8 give an unadjusted estimate of the RR 
of transmission, comparing the acute phase to the 
‘prevalent’ cases, of 8.25 (3.37–20.22) but since the 
risk of transmission in ‘prevalent’ cases is close to 
half of the risk in incident cases 6 to 15 months 
after sero-conversion, their estimate of the RR, 
using those in the incidence cohort who were 
infected 6 to 15 months after sero-conversion, 
would be 4.1 (1.6−10.1). This is still significantly 
higher than the indirect estimate given above, 
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especially since the Wawer et al.8 estimate is 
averaged over six months while the estimate made 
here is averaged over two months. In order to 
favour the importance of the acute phase on the 
epidemic we will use the high estimate from 
Wawer et al.8 
 Now, consider a cohort of newly infected 
people. Viral load varies considerably among 
people infected with HIV. From data on the 
distribution of viral load in a cross-sectional study 
from Orange Farm, South Africa12 (Bertran Auvert, 
personal communication) log10(viral load) 
measurements range from 2 to 6 corresponding to a 
range in the risk of transmission of 100 to 1000 
times. Allowing for the fact that those with the 
highest viral load will infect their partners and die 
more quickly,9 removing them from the pool of 
sero-discordant couples, the rate of transmissions 
will fall by about 50% after five years as shown in 
Figure 4 and observed by Wawer et al.8 (See 
Appendix 2 for details.) 
 
 
 
 
 
 
 
 
 
 
Figure 3. Variation of infectiousness as a function of time 
since infection in a cohort of people. No allowance is 
made for increased infectiousness during the acute phase 
but it is assumed that both infectiousness and mortality 
are highest in those with a high set-point viral load. 
 
 Hollingsworth et al.,10 using the data provided 
by Wawer et al.,8 use a modelling approach to 
determine the relative risk of transmission during 
the acute and chronic phases. Their estimate of the 
duration of the acute phase is DAP = 2.9 (1.2−6.0) 
months with RR = 26.2 (12.5−53.5). At the limits 
we can assume that the short estimate of DAP 
corresponds to the high value of RR while the long 
estimate of DAP corresponds to a low value of RR. 
Assuming that their comparison is with the sero-
prevalent couples one might again reduce the 
relative risk by a factor of about 2. An inevitable 
consequence of these estimates is that R0 must be 
close to 1 and indeed Hollingsworth et al.10 give an 
estimate of 2.2 under random mixing. If this were 
the case HIV should be much less stable than it is 
observed to be and small improvements in 
prevention should have a substantial impact on the 
epidemic which is not seen to be the case. Again, 
for the purposes of this analysis, we will use the 
high estimate from Hollingsworth et al.10 
 The estimates of DAP and RR that we will use in 
this analysis are given in Table 2. 
Table 2. Estimates of the duration of the acute phase, DAP, 
and the relative risk of transmission, RR, used in this 
analysis. 
 DAP (mo.) RR acute/chronic phase
This study 1 2.1 (1.1−3.9) 
Wawer8 6 8.2 (3.4−20.2) 
Hollingsworth10 2.9 (1.2−6.0) 26.2 (12.5−53.5) 
 
The impact of universal testing on 
transmission 
We now wish to explore the consequences for the 
different estimates of the acute phase duration and 
the relative infectiousness of the acute phase on the 
impact of T&T on transmission. The key point is 
this: one of the few directly observed parameters 
concerning the epidemiology of HIV is the initial 
doubling time which, in South Africa, is 1.25 ± 
0.25.11 Since the acute phase lasts for considerably 
less time than the chronic phase, the greater the 
relative risk of transmission in the acute phase the 
smaller must be the value of R0 to maintain the 
same initial doubling time. Indeed, if we know the 
initial doubling time (the growth rate r in Equations  
11 and 13 in Appendix 3) and we know the relative 
risk of infection in the acute phase and each of the 
four chronic phases (βi/β0 in Equations 7 to 9 in 
Appendix 3) and the duration of each of the four 
stages (1/ρi in Equations 7 to 9  and 10) in 
Appendix 3, then we can determine the values of 
the each of the individual ρi and hence the value of 
R0 (Equation 10 in Appendix 3). 
 Values of R0, as a function of the relative risk of 
transmission during the acute phase and the 
duration of the acute phase in months, are given in 
Figure 4A. Without ART the value of R0 is 5.8 
(brown rectangle). With RR = 2.1 and DAP = 2 mo. 
(green ellipse) R0 falls to 5.4. With RR = 8.3 and 
DAP = 6 mo. (red ellipse) R0 falls to 3.0. With RR = 
26 and DAP  = 6 mo. (blue ellipse) R0 falls to 2.3. 
As expected the higher the rate of transmission 
during the acute phase the lower the value of R0. 
 The boundaries of the ellipses indicate the 
uncertainty in the point estimates which are 
considerable. Assuming, as noted above, that in the 
Hollingsworth et al.10 study the high values of DAP 
correspond to low values RR, and vice versa, we 
slant the corresponding confidence ellipse at an 
appropriate angle. This also serves to show that if 
we let DAP = 6 mo. The Hollingsworth et al.10 and 
the Wawer et al.8 estimates are not significantly 
different.
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Figure 4. The value of R0 for an epidemic with a doubling time of 15 months as a function of the duration of the 
acute phase and the relative transmission rate in the acute phase compared to the chronic phase. Colours 
correspond to different values of R0 and the numbers in circles give the values on different contour lines. A 
without ART; B and C with random testing once a year or twice a year, on average; D and E with regular testing 
once a year or twice a year. Brown rectangle: RR = 1; green ellipse: RR = 2.1, DAP = 1 mo.; ellipse RR = 8.3, 
DAP = 6 mo.; blue ellipse: RR = 26, DAP= 3 mo. The size of the ellipse indicates the uncertainty in the estimate. 
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 Figure 4B shows what happens if people are 
tested randomly but once a year on average. With 
RR = 1, the value of R0 falls to 0.58 (brown 
rectangle). With RR = 2.1 and DAP = 2 mo. R0 falls 
to 0.61. With RR = 8.3 and DAP = 6 mo. R0 falls to 
0.84 and with RR = 26 and DAP  = 3 mo. R0 falls to 
0.90. In all three cases R0 still falls below 1 
although with the two higher estimates of RR it is 
only 10% to 20% below 1 which allows little 
margin of error. 
 Figure 4C shows what happens if the average 
testing interval is reduced to six months. With RR = 
1, R0 falls to 0.29 (brown rectangle). With RR = 2.1 
and DAP = 2 mo. R0 falls to 0.34. With RR = 8.3 
and DAP = 6 mo. R0 falls to 0.61 and with RR = 26 
and DAP  = 3 mo. R0 falls to 0.75. Even in the worst 
case (RR = 26, DAP = 3 mo.) R0 is significantly 
less than 1. 
 Figure 4D shows what happens if people are 
tested regularly once a year. With RR = 1, the value 
of R0 again falls to 0.29 (brown rectangle). With RR = 2.1 and DAP = 2 mo. R0 falls to 0.38. With RR = 
8.3 and DAP = 6 mo. R0 falls to 0.70 and with RR = 
26 and DAP  = 3 mo. R0 falls to 0.82. Again, even 
in the worst case (RR = 26, DAP = 3 mo.) R0 is 
significantly less than 1. 
 Figure 4E shows what happens if people are 
tested regularly twice a year. With RR = 1, R0 falls 
to 0.14 (brown rectangle). With RR = 2.1 and DAP = 2 mo. R0 falls to 0.21. With RR = 8.3 and DAP = 6 
mo. R0 falls to 0.45 and with RR = 26 and DAP  = 3 
mo. R0 falls to 0.68. Even in the worst case (RR = 
26, DAP  = 3 mo.) R0 is again significantly less than 
1. 
Conclusion 
We have three estimates of RR, the relative risk of 
infection, and DAP, the duration of the acute phase 
ranging from 2.1 over 2 months to 26.2 over 3 
months giving values of R0 ranging from 5.8 to 2.3. 
The high estimates for RR may well be over-
estimates. They are both based on the data from 
Rakai8 and discordant couple studies in which one 
partner is ‘sero-prevalent’ will select against those 
couples who are most infectious and therefore no 
longer sero-discordant. Furthermore, the high 
values of RR with long values of DAP imply values 
of R0 ≈ 2 which seems unlikely; if this were the 
case HIV should be relatively easy to eliminate 
through minor changes in behaviour and the 
epidemic should be much less stable.  
 However, it is clear from this analysis that even 
if we adopt the most pessimistic view and assume 
the relative risk of infection is 26 times higher 
during an acute phase that lasts for 3 months annual 
testing and immediate treatment has the potential to 
R0 to less than 1 and with any further contribution 
to prevention will probably guarantee elimination 
in the long term. Testing people regularly, on an 
annual basis, is considerably more effective than 
random testing because under random testing some 
people will be tested very frequently, which is not 
necessary, while others will be tested very 
infrequently which is not ideal. With regular testing 
even the most pessimistic view reduces R0 to 0.82 
and will probably lead to elimination. As expected, 
testing people twice a year reduces R0 even further 
and under all assumptions about the acute phase 
would guarantee elimination. 
 However, this analysis raises a possibility that 
may be even more important than considerations of 
high rates of infection during the acute phase. We 
know that the set point values of the viral load vary 
by several orders of magnitude. In the Fiebig7 study 
the log10(viral load) varies from about 2.6 to 5.6 in 
the chronic stage.  
 The data in Figure 4 suggest that variation in the 
average viral load in a cohort of people, as a 
function of time since infection, is likely to have a 
greater influence on the model predictions than any 
difference between acute and chronic phase 
transmission. However, there are two reasons why 
this is more difficult to allow for. First of all the 
result shown in Figure 4 assumes a relationship 
between survival and set-point viral load based on 
only one small study and better data are needed if 
this is to be made the basis for modelling the 
epidemic. Secondly, including this variation would 
probably need a model that includes the distribution 
of set-point viral loads explicitly and the structure 
of the models that are currently used does not allow 
for this. If this were to be explored further, the first 
priority would be to consider models in which the 
variation in the set-point viral load is included 
explicitly and comparisons made with a model in 
which this variation is set to zero. 
 We conclude, therefore, that increased 
transmission during the acute phase is unlikely to 
change the model predictions significantly for 
several reasons: 
1. The acute phase duration is more likely to be of 
the order of one or two months or about 1% to 
2% of the total disease duration. 
2. If transmission during the acute phase is 
sufficiently high for transmission during this 
short time to be important, then R0 must be 
correspondingly low and the reduction in R0 
needed for elimination is correspondingly less. 
3. There is strong evidence that transmission 
saturates above a viral load of about 4 to 5 logs 
mitigating the impact of even very high viral 
loads during the acute phase. 
4. A more important limitation of the current 
model structures, is that variation in the set-
point viral load is not included and this should 
be explored further. 
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5. The short duration of the acute phase means that 
it can only ever make a significant contribution 
to transmission if the rate of partner changes is 
much higher than is generally observed to be 
the case. 
Appendix 1. Fitting transmission as a 
power-law function of viral load 
Several authors13 have fitted the relationship 
between transmission and viral load to a power law 
function with the transmission increasing as the 
viral load to the power of about 0.3. This implies 
that at all viral loads transmission increases more 
slowly then linearly so that there is a degree of 
saturation in transmission as viral load increases. 
However, there is no obvious biological basis for 
this although from a statistical point of view it is 
not possible to choose between this power law 
model and the linear increase to an asymptote 
suggested here. 
Appendix 2. Reduction in transmission 
Let the relative risk of infection vary with time 
since infection as RR(t) Then under random testing 
at a rate ρ year, the reduction in the overall 
transmission will be 
 0
0
e ( )
( )
t RR t dt
RR t dt
R
ρ∞ −
∞
∫=
∫
 5 
while under regular testing at an interval of τ years 
the reduction in overall transmission will be 
 ( )0
0
1 ( )
( )
t RR t
RR t
R
τ
τ
∞
−∫=
∫
 6 
Since we have estimates of the relative risk of 
transmission, given that a person is alive, for 
different stages of infection, we approximate RR(t) 
with an appropriate step function. 
Appendix 3. R0 and the growth rate for 
an n-stage model 
We want to introduce an acute phase but also keep 
four chronic stages in order to ensure that the 
survival distribution approximates the observed 
Weibull distribution with a shape parameter of abut 
2 reasonably well. The equations for this model are 
(keeping the total population constant) 
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where I0 refers to the proportion of people that are 
susceptible people and Ii to the proportion in each 
successive stage of infection. The infectiousness of 
each stage is determined by βi and the mean 
duration of each stage is 1/ρi. From Equations 7 to 
9 it follows that 
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During the initial exponential growth of the 
epidemic at a rate r we have I0 ≈ 1 and  
 ,i
i
I r
I
=
i
    i = 0 to n 11  
from which it follows that  
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We can now determine the relationship between the 
relative risk of infection in each stage and R0 while 
constraining the overall growth rate, r, as follows. 
We first set the duration of each stage 1/ρi and the 
relative infectiousness of each stage βi/β0, for i = 1 
to n, and then vary β0 to get the required value of 
the initial growth rate r. Using Equation 10 we then 
calculate R0 directly. 
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